Neoplasms, Non-hematologic - Stage I-III Clinical Trial
Official title:
Detection of Tumor DNA in Blood Samples From Patients With Early Stage Cancer and "Healthy Controls"
The aim of this study is to employ genomic detection methodologies to measure the relative amount of tumor-derived nucleic acids in the blood of patients diagnosed with an early stage solid tumor who are either commencing, currently undergoing or have completed treatment. This approach will allow the investigators to develop a quantitative measure of therapy efficacy via the counting of the relative changes in tumor molecules over the course of treatment.
The aim of this study is to employ genomic detection methodologies to measure the relative
amount of tumor-derived nucleic acids in the blood of patients diagnosed with an early stage
solid tumor who are either commencing, currently undergoing or have completed treatment. This
approach will allow the investigators to develop a quantitative measure of therapy efficacy
via the counting of the relative changes in tumor molecules over the course of treatment.
The presence of circulating tumor-derived cfDNA in the plasma of patients can potentially
enable a non-invasive means of detecting the presence or absence of tumor, assessing tumor
burden and characterizing tumor biology in patients with cancer. The ability to measure the
distribution of circulating tumor DNA may allow determination of a quantitative tumor load
score in plasma that correlates to clinical tumor load. Clinical tumor load is a measure of
disease burden, and the investigators propose to test in this study whether the tumor load
score can measure this disease burden. A simple, reliable measure of disease burden would
have diverse utility during patient therapy.
;